E. Gantsgorn, A. Safronenko, E. V. Gubin, V. Vlasenko, E. V. Rashkova, I. M. Malleev, A. V. Ivanov, S. Gerasyuta, G. Bulguryan, YaO Osipenko, O. V. Denisenko, D. A. Saakyan, M. H. Ivanova
{"title":"Current Issues of the Use and Efficacy of Direct Oral Anticoagulants According their Pharmacogenetic Features","authors":"E. Gantsgorn, A. Safronenko, E. V. Gubin, V. Vlasenko, E. V. Rashkova, I. M. Malleev, A. V. Ivanov, S. Gerasyuta, G. Bulguryan, YaO Osipenko, O. V. Denisenko, D. A. Saakyan, M. H. Ivanova","doi":"10.33647/2074-5982-19-2-37-44","DOIUrl":null,"url":null,"abstract":"Despite the proven efficacy and relative safety of direct oral anticoagulants (DOAC), the issue of reducing the risk of complications associated with their use, depending on the genetic characteristics of patients, remains controversial. A personalized approach to the selection of DOAC should be developed. In this article, we review the available information on the feasibility of prescribing DOAC to patients with various diseases associated with hypercoagulation and on pharmacogenetic aspects of the DOAC application. The need for further research is substantiated, along with the importance of a wider introduction of the molecular-biological analysis of gene polymorphisms, whose presence affects the efficacy and safety of these drugs. In the course of the work, publications from the MedScape, PubMed, and eLIBRARY databases were analyzed.","PeriodicalId":14837,"journal":{"name":"Journal Biomed","volume":"37 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal Biomed","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33647/2074-5982-19-2-37-44","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Despite the proven efficacy and relative safety of direct oral anticoagulants (DOAC), the issue of reducing the risk of complications associated with their use, depending on the genetic characteristics of patients, remains controversial. A personalized approach to the selection of DOAC should be developed. In this article, we review the available information on the feasibility of prescribing DOAC to patients with various diseases associated with hypercoagulation and on pharmacogenetic aspects of the DOAC application. The need for further research is substantiated, along with the importance of a wider introduction of the molecular-biological analysis of gene polymorphisms, whose presence affects the efficacy and safety of these drugs. In the course of the work, publications from the MedScape, PubMed, and eLIBRARY databases were analyzed.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
